Northern Capital Management LLC Trims Position in Gilead Sciences, Inc. (GILD)
Northern Capital Management LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,255 shares of the biopharmaceutical company’s stock after selling 8,110 shares during the period. Northern Capital Management LLC’s holdings in Gilead Sciences were worth $1,292,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Seizert Capital Partners LLC lifted its stake in shares of Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after buying an additional 27,547 shares during the period. Investment Centers of America Inc. lifted its stake in shares of Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after buying an additional 1,958 shares during the period. Fagan Associates Inc. lifted its stake in shares of Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after buying an additional 845 shares during the period. Capital Asset Advisory Services LLC bought a new stake in shares of Gilead Sciences in the second quarter valued at about $875,000. Finally, First PREMIER Bank lifted its stake in shares of Gilead Sciences by 9.0% in the second quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock valued at $1,524,000 after buying an additional 1,787 shares during the period. Institutional investors and hedge funds own 74.38% of the company’s stock.
GILD has been the subject of several recent research reports. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. Royal Bank Of Canada initiated coverage on shares of Gilead Sciences in a research report on Thursday, September 14th. They issued an “outperform” rating and a $94.00 price target for the company. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Robert W. Baird reissued an “outperform” rating and issued a $87.00 price target on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Leerink Swann reissued a “hold” rating and issued a $74.00 price target on shares of Gilead Sciences in a research report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $85.92.
In related news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the sale, the executive vice president now directly owns 113,237 shares in the company, valued at $8,945,723. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $83.11, for a total transaction of $6,094,705.63. Following the sale, the insider now owns 2,996,766 shares in the company, valued at $249,061,222.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 446,819 shares of company stock worth $36,269,486. Insiders own 1.30% of the company’s stock.
Gilead Sciences, Inc. (GILD) opened at $73.77 on Friday. The firm has a market cap of $95,383.76, a price-to-earnings ratio of 7.62, a PEG ratio of -1.22 and a beta of 1.13. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a current ratio of 3.68, a quick ratio of 4.74 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period last year, the firm posted $2.75 earnings per share. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio is 23.69%.
WARNING: “Northern Capital Management LLC Trims Position in Gilead Sciences, Inc. (GILD)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/11/northern-capital-management-llc-trims-position-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.